Hung Te-Yu, Davis Timothy M E, Ilett Kenneth F, Karunajeewa Harin, Hewitt Sean, Denis Mey Bouth, Lim Chiv, Socheat Doung
Medicine Unit (Fremantle Hospital) and Pharmacology Unit (Queen Elizabeth 2 Medical Centre), School of Medicine and Pharmacology, University of Western Australia, Crawley, Western Australia, Australia.
Br J Clin Pharmacol. 2004 Mar;57(3):253-62. doi: 10.1046/j.1365-2125.2003.02004.x.
To study the population pharmacokinetics of piperaquine after co-administration with dihydroartemisinin in uncomplicated malaria.
The disposition of piperaquine was studied in 85 Cambodian patients with uncomplicated falciparum or vivax malaria treated with the piperaquine-dihydroartemisinin coformulation Artekin. All patients were given Artekin orally at 0, 6, 24 and 32 h with a total piperaquine dose of 32-35 mg base kg-1. Adults were given tablets while children received either tablets or a dispersible granule formulation. Patients underwent either intensive (17-19 samples) or sparse (2-5 samples) blood sampling schedules over 35 days and clinical/parasitological follow-up over > 28 days. Piperaquine in plasma was quantified by high performance liquid chromatography.
All patients achieved fever clearance within 24 h and parasite clearance within 72 h. The 28-day cure rate was 97% in adults and 98% in children. A covariate-free two-compartment population model with first-order absorption and elimination gave the most robust representation of the plasma concentration-time data in both adults and children. In adults (n = 38), the median (interquartile range) derived pharmacokinetic descriptors CL/F, Vss/F and t1/2,z were 0.9 l h-1 kg-1 (0.79-1.02 l h-1 kg-1), 574 l kg-1(371-711 l kg-1) and 23 days (19-28 days), respectively. In children (n = 47), corresponding values were 1.8 l h-1 kg-1 (1.29-2.3 l h-1 kg-1), 614 l kg-1 (332-1205 l kg-1) and 14 days (10-18 days), respectively.
Piperaquine is a highly lipid-soluble drug with a large Vss/F, long t1/2,z and a clearance that is markedly higher in children than in adults.
研究双氢青蒿素与哌喹联合应用于非复杂性疟疾患者后哌喹的群体药代动力学。
在85例柬埔寨非复杂性恶性疟或间日疟患者中研究哌喹的处置情况,这些患者接受哌喹 - 双氢青蒿素复方制剂Artekin治疗。所有患者在0、6、24和32小时口服给予Artekin,哌喹总剂量为32 - 35 mg碱基/kg-1。成人给予片剂,儿童接受片剂或可分散颗粒制剂。患者在35天内接受密集(17 - 19个样本)或稀疏(2 - 5个样本)采血方案,并进行超过28天的临床/寄生虫学随访。血浆中的哌喹通过高效液相色谱法定量。
所有患者在24小时内退热,72小时内疟原虫清除。成人28天治愈率为97%,儿童为98%。具有一级吸收和消除的无协变量二室群体模型最能有力地描述成人和儿童血浆浓度 - 时间数据。在成人(n = 38)中,推导的药代动力学描述符CL/F、Vss/F和t1/2,z的中位数(四分位间距)分别为0.9 l h-1 kg-1(0.79 - 1.02 l h-1 kg-1)、574 l kg-1(371 - 711 l kg-1)和23天(19 - 28天)。在儿童(n = 47)中,相应的值分别为1.8 l h-1 kg-1(1.29 - 2.3 l h-1 kg-1)、614 l kg-1(332 - 1205 l kg-1)和14天(10 - 18天)。
哌喹是一种高度脂溶性药物,Vss/F大,t1/2,z长,清除率在儿童中明显高于成人。